T. Miller

发表

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

D. Arnold, S. Muley, P. Vermersch, 2018, The Lancet Neurology.

Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.

B. Hayward, G. Pardo, F. Dangond, 2012, Multiple sclerosis and related disorders.

Severity and impact of xerostomia in patients treated with botulinum toxin type b for cervical dystonia: Observations on the quality of life of patients with xerostomia.

J. Massey, P. Charles, T. Miller, 2004, Current therapeutic research, clinical and experimental.

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study

B. Khatri, R. Gandhi, J. Nicholas, 2022, Multiple sclerosis journal - experimental, translational and clinical.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Jeffrey A. Cohen, D. Arnold, H. Hartung, 2012, The Lancet.

Repository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse.

T. Miller, M. Baker, Jeffrey Kaplan, 2021, Neurodegenerative disease management.

A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse

T. Miller, M. Baker, Jeffrey Kaplan, 2020, Frontiers in Neurology.

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

E. Celius, G. Comi, T. Ziemssen, 2020, Neurology and Therapy.

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Alexander Parajeles Vindas, P. Kowey, D. Arnold, 2016, Neurology. Clinical practice.

Effect of Alemtuzumab Infusions on Vital Signs: A Prospective Observational Study in Patients with Relapsing-Remitting Multiple Sclerosis.

C. Laganke, D. Graves, A. Jacobs, 2019, International journal of MS care.

Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis.

B. Hayward, R. Bennett, F. Dangond, 2013, Multiple sclerosis and related disorders.

Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101)

Jeffrey A. Cohen, D. Arnold, H. Weiner, 2013 .

Relapse Outcomes with Alemtuzumab vs IFNB-1a in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.098)

D. Arnold, X. Montalban, H. Weiner, 2013 .

Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.

B. Hayward, G. Pardo, F. Dangond, 2012, Multiple sclerosis and related disorders.